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Abstract
Purpose To ﬁnd the maximum tolerated dose (MTD) of
OSI-461 in combination with mitoxantrone in patients with
advanced solid tumors.
Methods This was a Phase I study using cohort dose
escalation of OSI-461 dosed orally twice daily in combi-
nation with mitoxantrone 12 mg/m
2 given on Day 1 of
each 21-day cycle.
Results OSI-461 dose was escalated to 1,000 mg po bid.
One patient experienced a dose-limiting toxicity (DLT).
Three patients discontinued the study due to adverse events
(AE). Two patients (10%) had a partial response, and ten
patients (50%) had stable disease as best response.
Conclusion The combination of OSI-461 and mitoxan-
trone was well tolerated. Dose escalation was stopped
because of toxicities in a concurrent Phase I trial. The
response rate seen in patients with prostate cancer was
comparable to response rates seen in trials of mitoxantrone
and prednisone alone, and further studies of the combina-
tion of OSI-461 and mitoxantrone were not pursued.
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Introduction
OSI-461 is a second generation selective apoptotic anti-
neoplastic drug (SAAND). SAANDs induce apoptosis of
tumor cells by inhibiting 30,50-cyclic guanosine mono-
phosphate (cGMP) phosphodiesterase (PDE) isoforms
PDE2 and PDE5, elevating cGMP, activating protein
kinase G (PKG) and decreasing b-catenin [1]. OSI-461 has
approximately 1009 more afﬁnity for cGMP PDE than
does exisulind, a ﬁrst generation SAAND compound.
In vitro data suggest that OSI-461 inhibits angiogenesis
and blocks mitotic progression through disruption of
microtubule organization and spindle formation [2]. OSI-
461 induces apoptosis in a wide variety of epithelial-
derived and non-epithelial-derived tumor cell lines while
sparing normal cells. Nude mice with human prostate
adenocarcinoma xenografts showed a decrease in tumor
size when treated with mitoxantrone and OSI-461 when
compared to animals treated with either mitoxantrone or
OSI-461 alone.
Mitoxantrone is a commercially available synthetic
cytotoxic antineoplastic anthracenedione derivative
approved by the FDA and used routinely in combination
with corticosteroids for the treatment of patients with
advanced hormone-refractory prostate cancer. It has also
been extensively studied in the treatment of breast cancer,
leukemia and lymphoma. Mitoxantrone causes crosslinks
and strand breaks in DNA, interferes with RNA and
inhibits topoisomerase II.
OSI-461 is a cytostatic agent that has shown modest
antitumor activity in a Phase II pilot study involving
patients with hormone-refractory prostate cancer. The
combination of cytostatic agents with standard cytotoxic
therapies is under intensive evaluation, and the combina-
tion of OSI-461 and mitoxantrone, which showed evidence
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appeared worthwhile to investigate both from a pharma-
cologic and from a clinical perspective. In addition, both
agents have demonstrated activity in patients with hor-
mone-refractory prostate cancer. Therefore, we conducted
a Phase I dose-ﬁnding study of OSI-461 orally twice daily
in combination with mitoxantrone dosed on Day 1 of each
21-day cycle.
Patients and methods
Study design
This was a two-center, open-label Phase I study using a
3 ? 3 cohort dose escalation design to determine the
maximum tolerated dose (MTD) of OSI-461 po bid that
can be given in combination with mitoxantrone to
patients with advanced solid tumors. Secondary objec-
tives included describing the pharmacokinetic (PK) data
and toxicity proﬁles (including any correlations between
these proﬁles) and evaluating the anticancer activity of
OSI-461 and mitoxantrone in combination. This study
was approved by the appropriate Institutional Review
Boards, and all enrolled patients provided written
informed consent.
Patient selection
Patients were eligible for this study if they met all of the
following inclusion criteria: histologically documented
solid tumor (measurable or non-measurable) potentially
responsive to mitoxantrone and for which no effective
therapy was available; age C18 years; ECOG performance
status 0–2; predicted life expectancy C12 weeks. Patients
may have had any number of prior chemotherapy or radi-
ation therapy regimens, but a minimum of 4 weeks must
have elapsed between the end of previous therapy and entry
into the protocol. Patients previously exposed to anthra-
cyclines may not have exceeded a cumulative anthracy-
cline dose of 250 mg/m
2 of Adriamycin. Patients were
required to have adequate bone marrow, hepatic and renal
function as deﬁned by the following: neutrophil count
C1.5 9 10
9/L; platelets 100 9 10
9/L; total bilirubin B
upper limit of normal; ALT and AST B2.5 9 upper limit
of normal; and serum creatinine B2.0 mg/dL. Patients were
also required to have adequate cardiac function with an
estimated left ventricular ejection fraction of C50%.
Patients were excluded if they had a history of previous
myocardial infarction, cerebrovascular accident or uncon-
trolled atrial ﬁbrillation within 1 year of screening. Con-
current use of prednisone or luteinizing hormone-releasing
hormone (LHRH) was permissible.
Treatment plan and dose escalation
The starting dose of OSI-461 was 200 mg po taken once on
Cycle 1, Day 1 and twice daily from Day 2 onward.
Mitoxantrone was given at 12 mg/m
2 as a 30-min IV
infusion starting on Cycle 1, Day 1 and repeated on Day 1
of every 21-day cycle. On Day 1 of Cycles 1 and 2, patients
were instructed to eat a high-fat, high-calorie meal within
30 min of the scheduled dosing time. On other days of the
study, patients took OSI-461 with 8 oz of water and within
30 min of eating.
An initial cohort of three patients was treated at each
dose level. Dose escalation did not occur until the last
patient treated in the previous cohort had been observed for
one complete cycle of therapy. If no patients in a given
cohort experienced a dose-limiting toxicity (DLT), the
OSI-461 dose was escalated by 200 mg bid. If one patient
in a given cohort experienced a DLT, three additional
patients were enrolled at the same dose of OSI-461 and
observed. If no additional DLTs were observed, then dose
escalation continued. Once a second patient in a given
cohort experienced a DLT, dose escalation was stopped,
and the MTD was to be deﬁned as the dose level below
which C33% of patients experienced a DLT. The MTD
was expanded to a maximum of 10 patients to further
evaluate safety and pharmacokinetics at this dose level.
Toxicities were graded according to the National Cancer
Institute Common Terminology Criteria for Adverse
Events v3.0 (NCI CTCAE). A DLT was any toxicity that
was considered at least possibly related to protocol therapy
and was experienced during the ﬁrst cycle of therapy. DLT
was deﬁned as the following: Cgrade 3 non-hematologic
toxicity (excluding inadequately treated nausea, vomiting
and/or diarrhea), grade 4 neutropenia for C7 days, febrile
neutropenia (grade 3 neutropenia associated with fever
C38.5C), grade 4 thrombocytopenia or bleeding requiring
a platelet transfusion, or treatment delay of 14 days or
greater because of treatment-related toxicity. Patients
experiencing a DLT were permitted to continue treatment
at the next lower dose level of OSI-461.
Doses were also adjusted or delayed for toxicities. If a
patient experienced several toxicities, dose adjustments
were made according to the system showing the greatest
degree of toxicity (reducing the dose to the lowest level).
OSI-461 dose was held for Cgrade 3 elevated transami-
nases or Cgrade 1 bilirubinemia. OSI-461 dose was
decreased 50% for grade 2 elevated transaminases.
Mitoxantrone was discontinued for decreases in left ven-
tricular ejection fraction of 10% or greater. Mitoxantrone
dose was reduced one dose level for grade 4 neutropenia,
febrile neutropenia, documented infection with Grade 3/4
neutropenia or grade 4 thrombocytopenia. Mitoxantrone
was held for up to 14 days for grade 2 elevated
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123transaminases or grade 1 bilirubinemia. OSI-461 and
mitoxantrone were held for other grade 3 non-hematologic
toxicities until these resolved, and OSI-461 and mitoxan-
trone doses were then decreased by one dose level.
Patients were continued on protocol in the absence of
disease progression or unacceptable toxicity. Study medi-
cation was discontinued in the event of disease progression,
unacceptable toxicity, patient death, patient request or for
medical/ethical reasons.
Study procedures
Prior to enrollment, patients underwent a complete medical
history review, physical exam, laboratory assessment, and
MUGA or echocardiogram. A repeat physical examination
was done on Day 1 of each subsequent cycle. Laboratory
assessments were obtained weekly during Cycles 1 and 2
and on Days 1 and 8 of subsequent cycles. MUGA or
echocardiogram was repeated every second cycle. Tumor
evaluations were done at baseline and then after every
second cycle. Response and progression were evaluated
using the Response Evaluation Criteria in Solid Tumors
(RECIST) guidelines [3]. Prostate-speciﬁc antigen (PSA)
was measured at baseline and at the beginning of each
cycle of treatment for all patients with prostate cancer.
Time to PSA progression as deﬁned by the Prostate Cancer
Clinical Trials Working Group (PCWG2) was calculated
when possible [4]. All patients who received at least one
dose of OSI-461 were included in the safety analysis. All
patients who received at least one cycle of therapy and had
their disease re-evaluated were included in the efﬁcacy
analysis.
Pharmacokinetics
Blood samples for pharmacokinetic (PK) analysis were
drawn on Day 1 (predose OSI-461 and preinfusion
mitoxantrone, immediately after mitoxantrone infusion,
and 15, 30 min, 1, 2, 4, 7 and 9 h postinfusion), Day 2
(24 h postinfusion and predose OSI-461), Day 3 or 4
(morning), Day 5 or 6 (morning), and Day 8 (morning) of
Cycles 1 and 2. An additional blood sample was collected
on Day 22 (predose OSI-461 and preinfusion mitoxan-
trone) of Cycle 2.
Plasma from heparinized blood samples was analyzed
by a validated liquid chromatography/mass spectrometry
method. Pharmacokinetic parameters of OSI-461 and
mitoxantrone were computed for each patient by non-
compartmental analyses using WinNonlin
 5.2 (Pharsight
Corporation, Mountain View, CA). Actual blood collection
times were used in constructing the tables of individual
plasma concentrations of OSI-461 and mitoxantrone and
for calculation of PK parameters.
Results
Patient characteristics
The demographic characteristics of the patients enrolled in
the study are shown in Table 1. Most patients had received
two or more chemotherapy regimens as well as radiation
therapy. One patient was enrolled but never treated because
of decline in performance status prior to the ﬁrst cycle of
treatment.
Dosing
Three patients each were treated at OSI-461 200, 400, 600
and 800 mg po bid without DLT. Eight patients were
treated at OSI-461 1,000 mg po bid. This was the maxi-
mum dose level studied in this trial because of toxicities
seen in a concurrent Phase I study of single-agent OSI-461.
Patients were on study for a mean of 57, 74, 69, 179 and
70 days at OSI-461 200, 400, 600, 800 and 1,000 mg po
bid, respectively.
Beyond cycle 1, six patients (30%) had their OSI-461
doses modiﬁed, including two patients at OSI-461 600 mg
po bid, one patient at OSI-461 800 mg po bid and three
patients at OSI-461 1,000 mg po bid. Reasons for OSI-461
dose modiﬁcations included elevated bilirubin (two
patients), neutropenia (two patients) and elevated liver
enzymes and rash (one patient each).
The total number of mitoxantrone cycles was 10, 10, 9,
19 and 26 at OSI-461 200, 400, 600, 800 and 1,000 mg po
Table 1 Patient characteristics
Entered/treated 21/20
Male/female 16/4
Median age in years (range) 61 (48–81)
ECOG PS
0 7 (35%)
1 10 (50%)
2 2 (10%)
Missing 1 (5%)
Primary tumor
Prostate 14 (70%)
Breast 4 (20%)
Bladder 1 (5%)
Testicular 1 (5%)
Prior chemotherapy regimens
0–1 6
2–3 9
4? 5
Prior radiotherapy, yes/no 15/5
Cancer Chemother Pharmacol (2011) 67:431–438 433
123bid, respectively. There were no mitoxantrone dose
reductions at OSI-461 200, 600 or 800 mg po bid. There
was one mitoxantrone dose reduction at OSI-461 400 mg
po bid in cycle 6 for grade 4 neutropenia. There were two
mitoxantrone dose reductions at OSI-461 1,000 mg po bid,
one in cycle 2 due to grade 3 rash and one in cycle 3 due to
grade 4 neutropenia.
Toxicities and adverse events
Twenty patients (100%) experienced at least one adverse
event, and 17 patients (85%) experienced an adverse event
considered related to OSI-461 and/or mitoxantrone. The
most common AEs included GI events and fatigue, which
were generally of severity grade 1 or 2. A summary of AEs
and toxicities reported for all cycles is shown in Table 2.
There were two treatment-related grade three adverse
events: hearing loss in one patient in the OSI-461 800 mg
po bid cohort and one in cycle 2 due to grade 3 erythem-
atous rash in one patient at OSI-461 1,000 mg po bid.
Another patient at OSI-461 1,000 mg po bid experienced a
DLT (grade 4 neutropenia for C7 days) that was consid-
ered to be due to mitoxantrone. Eight patients experienced
at least one serious adverse event (SAE), none of which
were related to study drug.
Most patients experienced hematologic laboratory
abnormalities that did not qualify as a DLT, including
70% of patients with grade 3/4 lymphopenia and 65% of
patients with grade 3/4 neutropenia and leukopenia. No
patients had febrile neutropenia. The median duration of
grade 3 or grade 4 leukopenia was 7 days (range 3–
42 days). Fifty ﬁve percent of patients experienced
transaminase elevation, though this was mostly low grade
and transient. One patient at OSI-461 1,000 mg po bid
had the OSI-461 dose reduced by 50% due to grade 2
ALT/AST, but the ALT continued to increase to grade 3
at which time the patient was taken off study due to
progressive disease. Three patients (15%) experienced an
absolute LVEF decrease of 10% or greater: one patient at
OSI-461 400 mg po bid had a 12% decrease after 2
cycles; one patient at OSI-461 1,000 mg po bid had a
12% decrease after six cycles; and one patient at OSI-461
1,000 mg po bid had a 29% decrease after eight cycles
(this patient’s LVEF returned to normal after discon-
tinuing mitoxantrone).
Three AEs resulted in patient discontinuation from the
study. One patient at OSI-4611,000 mg po bid had a
treatment-related SAE (Grade 3 rash) in Cycle 2 that
resulted in discontinuation. Two additional patients had
non-treatment-related AEs that resulted in discontinuation,
including one patient at OSI-461 200 mg po bid with
hyponatremia and another patient at OSI-461 400 mg po
bid with pneumonia.
Disease response
Twelve of the 20 treated patients (60%) had either stable
disease (10 patients) or a partial response (two patients) as
their best measured response by RECIST guidelines. One
patient with prostate cancer whose disease had previously
progressed on hormonal therapy, docetaxel and estramus-
tine had a conﬁrmed partial response after cycle 8 at OSI-
461 400 mg po bid. One patient with breast cancer whose
disease had previously progressed on hormonal therapy and
ﬁve different chemotherapy regimens (including two
investigational agents) had a partial response after cycle 8
at OSI-461 800 mg po bid. The range of duration of stable
disease was two to eight cycles.
Fourteen patients had evidence of progressive disease at
the time of discontinuation from the study. The overall
median time to progression from date of ﬁrst treatment was
48 days. The median times to progression for patients
treated at OSI-461 200 mg po bid, 400 mg po bid, 600 mg
po bid, 800 mg po bid and 1,000 mg po bid were 33, 53,
53, 236 days (one patient) and 52 days, respectively.
Seven of the 14 patient with prostate cancer patients
(50%) experienced either a partial response (one patient) or
stable disease (six patients) per RECIST as their best
response at their ﬁrst planned imaging after two cycles.
The median time to disease progression for patients with
prostate cancer was 48 days. All four of the patients with
breast cancer had a partial response (one patient) or stable
disease (three patients) as their best response.
Two of the 14 patients with prostate cancer (14%) treated
had aPSA response (decreasesintheir PSA levels of 50%or
more when compared to pretreatment baseline levels). One
of these patients was treated at OSI-461 400 mg po bid and
had previous disease progression on hormonal therapy and
chemotherapy (docetaxel and estramustine), and the other
was treated at OSI-461 1,000 mg po bid and also had pre-
vious disease progression on hormonal therapy and che-
motherapy (amonaﬁde and docetaxel).
Ten patients with prostate cancer did not have decreases
in their PSA levels and did not remain on trial at least
12 weeks as required to calculate time to PSA progression
as deﬁned by the PCWG2. The four patients with prostate
cancer who experienced any decline in their PSA levels
had times to PSA progression of 63 days (not conﬁrmed),
84 days (conﬁrmed), 120 days (conﬁrmed) and 169 days
(conﬁrmed).
Pharmacokinetics
OSI-461 peak plasma concentration and exposure
increased linearly in proportion to dose within the OSI-461
dose range tested (200–1,000 mg po bid). As detailed in
Fig. 1a and Table 3, there were no signiﬁcant differences
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123between the different AUC parameters of OSI 461 from
Cycle 1 to Cycle 2, indicating a lack of accumulation at
steady state. Also, there was no signiﬁcant relationship
between dosing level and clearance rate or half-life.
Finally, the pharmacokinetic parameters for mitoxantrone
were not signiﬁcantly affected by OSI-461 at any dose
level tested (Fig. 1b and Table 4).
Discussion
OSI-461 is a second generation SAAND, a class of anti-
neoplastic drugs that induce apoptosis by inhibiting cGMP
phosphodiesterase isoforms PDE2 and PDE5. Exisulind
was a ﬁrst generation SAAND compound and was exten-
sively studied in combination with chemotherapy in a
variety of tumor types, including prostate cancer. A Phase
I/II study of oral exisulind twice daily in combination with
docetaxel given in a 3-week cycle was performed in
patients with hormone-refractory prostate cancer [5]. The
PSA response rate for patients treated with the Phase II
dose was only 23%, and the combination was not explored
further. Another Phase II trial explored the combination of
twice daily oral exisulind in combination with weekly
docetaxel in patients with hormone-refractory prostate
cancer [6]. Approximately 20% of patients had a PSA
response, and this combination regimen was also not
explored further. Additional Phase II studies of exisulind in
combination with chemotherapy in lung cancer also failed
to show sufﬁcient efﬁcacy to warrant further study [7–9].
OSI-461 has approximately 1009 more afﬁnity for
cGMP PDE than does exisulind, a ﬁrst generation SAAND
compound. OSI-461 inhibited the growth of prostate cancer
cell lines in vitro, and in a pilot Phase II study, OSI-461
showed modest antitumor activity in patients with hor-
mone-refractory prostate cancer [10]. Mitoxantrone is
Table 2 Adverse events and laboratory toxicities by maximum grade for all cycles
OSI-461 Dose (PO bid) Total
200 mg 400 mg 600 mg 800 mg 1000 mg
All 3/4 All 3/4 All 3/4 All 3/4 All 3/4 All 3/4
All AEs (regardless of causality)
Fatigue 2 0 1 0 2 0 1 0 4 1 10 (50%) 1 (5%)
Nausea 2 0 2 0 3 0 2 0 1 0 10 (50%) 0
Back pain 1 0 2 0 1 1 2 0 1 1 7 (35%) 2 (10%)
Diarrhea 1 0 1 0 1 0 1 0 3 0 7 (35%) 0
Arthralgia 1 1 1 0 1 1 1 0 2 0 6 (30%) 2 (10%)
Constipation 1 0 1 0 1 0 0 0 3 0 6 (30%) 0
Vomiting 2 0 1 0 2 0 0 0 0 0 5 (25%) 0
Cough 0 0 2 0 1 0 1 0 1 0 5 (25%) 0
Decreased appetite 1 1 0 0 1 0 1 0 1 0 4 (20%) 1 (5%)
Dysgeusia 0 0 0 0 0 0 3 0 1 0 4 (20%) 0
Anorexia 0 0 0 0 0 0 1 0 3 0 4 (20%) 0
Dehydration 1 0 1 0 1 0 0 0 1 0 4 (20%) 0
Headache 0 0 1 0 0 0 3 0 0 0 4 (20%) 0
Treatment-related AEs
Nausea 2 0 2 0 3 0 1 0 0 0 8 (40%) 0
Fatigue 1 0 1 0 1 0 1 0 2 0 6 (30%) 0
Diarrhea 0 0 1 0 1 0 1 0 2 0 5 (25%) 0
Vomiting 2 0 1 0 2 0 0 0 0 0 5 (25%) 0
Constipation 1 0 0 0 1 0 0 0 2 0 4 (20%) 0
Dysgeusia 0 0 0 0 0 0 3 0 1 0 4 (20%) 0
Laboratory toxicities
Neutropenia 2 1 3 1 3 2 3 3 8 6 19 (95%) 13 (65%)
Leukopenia 3 1 3 1 3 3 3 3 8 5 20 (100%) 13 (65%)
Lymphopenia 3 1 2 2 3 3 3 2 8 6 19 (95%) 14 (70%)
Transaminitis 1 0 2 0 2 0 1 0 5 1 11 (55%) 1 (5%)
Bilirubinemia 1 0 0 0 1 0 0 0 3 0 5 (25%) 0
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123commonly used in combination with corticosteroids for the
treatment of hormone-refractory prostate cancer and is also
used in other tumor types, including breast cancer. Thus,
we conducted a Phase I dose-ﬁnding study of OSI-461
given orally twice daily in combination with mitoxantrone
dosed on Day 1 of a 21-day cycle.
The combination regimen explored in this study was
well tolerated, and only one DLT was observed at the
highest OSI-461 dose level studied (Dose Level 4, OSI-461
1,000 mg po bid). Of the three AEs that resulted in patient
discontinuation from the study, only one (Grade 3 rash)
was felt to be treatment related. The most common AEs
included GI events and fatigue, and all of these were
BGrade 2 in severity. Severe hematologic toxicities such as
grade 3/4 neutropenia, leukopenia and lymphopenia were
common, but no episodes of febrile neutropenia were
observed.
Dose escalation was not continued above OSI-461
1,000 mg po bid because of toxicities seen in a concurrent
Phase I study of single-agent OSI-461 in patients with
advanced solid tumors. In that study, three DLTs of Grade
3 abdominal pain were seen at the OSI-461 dose level of
A
B
Fig. 1 Median plasma OSI-461
concentrations at each OSI-461
dose level for Cycles 1 and 2 (a)
and the median plasma
mitoxantrone concentrations at
each OSI-461 dose level for
Cycles 1 and 2 (b)
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1231200 mg po bid. This was thought to be due to gelatin
accumulation in the gastrointestinal tract from the large
number of capsules ingested (24 capsules per day). Two
additional DLTs (Grade 3 abdominal pain and Grade 3
fatigue) were seen in the single-agent Phase I study at the
OSI-461 dose level of 1,000 mg po bid, and the MTD of
OSI-461 for that study was determined to be 800 mg po
bid.
While the primary objective of this study was to ﬁnd the
MTD of the combination of OSI-461 dosed twice daily
with mitoxantrone dosed on Day 1 of each 21-day cycle, a
secondary objective was to evaluate the activity of this
regimen. While 12 of the 20 patients (60%) treated had
either stable disease or a partial response as their best
measured response, only ﬁve (25%) had stable disease or a
partial response that persisted beyond the ﬁrst two cycles of
treatment.
Fourteenofthepatientsenrolledinthisstudyhadprostate
cancer, and only four (29%) of these patients had decreases
in their PSA levels. Of these four patients, only two had a
PSA response (decrease of C50% from their baseline lev-
els). Of the eight patients treated at the highest dose level
(Dose Level 4, OSI-461 1,000 mg po bid), seven had pros-
tate cancer. Only two of these patients (29%) had a PSA
response. For comparison, mitoxantrone and prednisone
demonstrated a PSA response in 32% and 27% of patients in
the TAX 327 and SWOG 9916 trials, respectively [11, 12].
Thus, the responses seen in this study may have been due to
mitoxantrone and not the combination of OSI-461 and
mitoxantrone. Based on the results of this study, in addition
to the results of the TAX 327 and SWOG 9916 trials, further
investigation into the combination of twice daily OSI-461 in
combination with mitoxantrone given every 3 weeks was
not pursued.
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